News from specialised therapeutics australia pty ltd A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 17, 2014, 17:40 ET

Specialised Therapeutics Australia: Updated Pancreatic Cancer Data Presented at International Cancer Conference

- Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit - First Phase III trial in...

Jan 07, 2014, 08:00 ET

Specialised Therapeutics Australia Partners with Genomic Health Inc. to Deliver Novel Genomic Test to Breast Cancer Patients

 Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive...

Jan 23, 2013, 20:47 ET

ABRAXANE® más gemcitabine mejora la supervivencia en el estudio de fase III de pacientes con cáncer pancreático avanzado

- ABRAXANE más gemcitabine demostró unos resultados estadística y clínicamente significativos en los criterios primarios y...

Jan 23, 2013, 20:12 ET

L'ABRAXANE® associé à la gemcitabine améliore la survie des patients atteints de cancer du pancréas avancé dans une étude de phase III

- L'ABRAXANE associé à la gemcitabine a démontré des résultats statistiquement et cliniquement très significatifs...

Jan 22, 2013, 18:00 ET

ABRAXANE® Plus Gemcitabine Improves Survival in Phase III Study of Patients with Advanced Pancreatic Cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast...

Oct 26, 2012, 08:50 ET

ABRAXANE® demuestra una mejora destacada en la supervivencia libre de progresión frente a la quimioterapia estándar

- ABRAXANE® demuestra una mejora destacada en la supervivencia libre de progresión en comparación con la quimioterapia estándar...

Oct 25, 2012, 16:45 ET

ABRAXANE® montre une amélioration significative de la survie sans progression comparativement à la chimiothérapie standard chez les patients atteints de mélanomes avancés

- ABRAXANE parvient à presque doubler la survie sans progression en essai clinique de phase III (4,8 mois vs. 2,5 mois...

Oct 25, 2012, 16:40 ET

ABRAXANE® zeigt deutliche Verbesserung der progressionsfreien Überlebenszeit im Vergleich zu einer Standard-Chemotherapie bei Patienten mit fortgeschrittenem Melanom

- ABRAXANE-Behandlung zeigt fast doppelt so langes progressionsfreies Überleben in der Phase-III-Studie - 4,8 Monate im Vgl. zu 2,5 Monaten in...

Oct 25, 2012, 07:30 ET

ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients

Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge